Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Color
NCT06949111Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2025
- Primary completion
- May 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in colon cancer, sponsored by The Fourth Hospital of Hebei Medical University. Started May 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06949111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06949111.